Market Place
Sourcing Support
Ventus to move daily oral lupus prospect into phase 2 testing
31 Oct 2024 //
FIERCE BIOTECH
Ventus Completes Phase 1 Trial of VENT-03, cGAS Inhibitor
31 Oct 2024 //
BUSINESSWIRE
Ventus Therapeutics Expands Montreal Presence With New Facility
16 Jul 2024 //
BUSINESSWIRE
Ventus’ partner Novo Nordisk first participant in ph 1 study for NNC6022-0001
07 May 2024 //
PHARMABIZ
Ventus Doses First In NLRP3 Inhibitor Study For Novo Nordisk
03 May 2024 //
BUSINESSWIRE
Ventus to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
08 Apr 2024 //
BUSINESSWIRE
Ventus Therapeutics Initiates Clinical Testing of VENT-03
03 Jan 2024 //
BUSINESSWIRE
Ventus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
Ventus Therapeutics to Present at the Stifel 2023 Healthcare Conference
09 Nov 2023 //
BUSINESSWIRE
Ventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
06 Sep 2023 //
BUSINESSWIRE
Ventus Therapeutics Initiates Dosing in a Phase 1 Clinical Trial of VENT-02
22 Aug 2023 //
BUSINESSWIRE
Ventus Therapeutics to Present at Canadian Chemistry Conference and Exhibition
01 Jun 2023 //
BUSINESSWIRE
Ventus Therapeutics Hosts Inaugural Program Spotlight: VENT-03
01 May 2023 //
BUSINESSWIRE
Ventus Therapeutics Awarded Grant by The Michael J. Fox Foundation
20 Apr 2023 //
BUSINESSWIRE
Ventus Therapeutics Provides Updates on cGAS Inhibitor Program at
17 Apr 2023 //
BUSINESSWIRE
Ventus Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
05 Jan 2023 //
BUSINESSWIRE
Ventus Nominates cGAS Inhibitor VENT-03 as Inaugural Development Candidate
04 Jan 2023 //
BUSINESSWIRE
Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Summit
01 Dec 2022 //
BUSINESSWIRE
Ventus CSO Michael Crackower to Present on ReSOLVE Platform at Conference
06 Oct 2022 //
BUSINESSWIRE
Ventus Therapeutics Enters Agreement with Novo for NLRP3 Inhibitor Program
01 Oct 2022 //
PRESS RELEASE
Novo Nordisk Sinks $70M Cash into Ventus` NLRP3 Inhibitor
30 Sep 2022 //
BIOSPACE
Ventus sells its lead drug candidate to Novo Nordisk
29 Sep 2022 //
BIOPHARMADIVE
Ventus Opens New Facility in Waltham, MA as First Phase of Global Expansion
06 Sep 2022 //
BUSINESSWIRE
Ventus Therapeutics Promotes Daniel Koerwer to Chief Operating Officer
07 Jul 2022 //
BUSINESSWIRE
Ventus Therapeutics Awarded Grant by the U.S. Department of Defense
09 May 2022 //
BUSINESSWIRE
Ventus Therapeutics Appoints Stuart Green, M.D., as Chief Medical Officer
02 May 2022 //
BUSINESSWIRE
Ventus Tx Appoints Victor Lobanov, PhD, as Head of Computational Sciences
04 Apr 2022 //
BUSINESSWIRE
Ventus Therapeutics Appoints Christine Ha as Chief Financial Officer
31 Mar 2022 //
BUSINESSWIRE
Ventus Therapeutics raises funding to expedite drug discovery platform
10 Feb 2022 //
PHARMACEUTICAL-TECHNOLOGY
Ventus Therapeutics Closes $140 Million Series C Financing
09 Feb 2022 //
BUSINESSWIRE
Ventus to Present Data for Novel Brain-Penetrant NLRP3 Small Molecule Inhibitors
18 Nov 2021 //
BUSINESSWIRE
Ventus Therapeutics to Present Data on Novel cGAS Small Molecule Inhibitors
03 Nov 2021 //
BUSINESSWIRE
Ventus Therapeutics Closes $100 Million Series B Financing
07 Apr 2021 //
BUSINESSWIRE
